AGL · NYSE · Medical - Care Facilities

Agilon Health (AGL)

Enables primary-care groups to run Medicare-focused risk-bearing care models.

$83.44
vs last close−3.40 (−3.92%)
Loading prices…

Agilon Health, Inc.AGL
Health Care

Helps community primary-care groups move Medicare senior care into value-based arrangements, mainly through Medicare Advantage capitation. The model combines the agilon platform, long-term physician partnerships, and a physician network, with revenue tied to payor contracts and federal healthcare programs.

Partners with community-based primary-care physician groups in the United States, forming local risk-bearing entities that contract with Medicare Advantage payors. The operating model centers on the agilon platform, long-term physician partnerships, and the agilon network.

Provides technology, people, process, and capital so physician partners can identify care gaps, integrate with payors, and manage quality and cost outcomes. Medical services revenue comes mainly from capitation arrangements for attributed Medicare Advantage members.

Also participates in CMS ACO Models through equity-method investments, while most consolidated revenue remains Medicare Advantage-linked. The business depends on payor contracts, CMS payment rates, risk adjustment, member attribution, claims data, and physician partners' execution under value-based care arrangements.

Company facts

CEOTim O'Rourke
ListedApr 15, 2021
ExchangeNYSE
HeadquartersWesterville, OH
CountryUnited States
Employees856
CIK0001831097
ISINUS00857U2069

Market cap$1.45B
EPS (ttm)−$15.41
P/E (ttm)−5.64
ROE-119.3%
P/B6.37
P/S0.2447
Dividend yieldDiv yield
Beta2.46vs XLV 0.46

Price target$112.00+29.0%Average of 25 analysts
ConsensusHold14 of 25 analysts
Ratings

Target rangeAs of Sep 22, 2026

Latest analyst notes

DateFirmActionPriorCurrent
Sep 15, 2026BernsteinUpgrade
Rating: Market PerformTarget:
Rating: OutperformTarget: $125
Sep 15, 2026RBC CapitalTarget
Target:
Target: $125
Aug 11, 2026Wells FargoReiterate
Rating: Target: $141
Rating: OverweightTarget: $146
Aug 11, 2026CitigroupUpgrade
Rating: Sell
Rating: Neutral
Aug 10, 2026CitigroupUpgrade
Rating: Sell
Rating: Neutral

Next report
Nov 3, 26
in 41 days
EPS estimate
−$1.22
Revenue estimate
$1.46B
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported−$6.50$0.73−$6.25−$6.75−$11.50$1.80$1.04Pending
Estimate−$0.18−$0.07−$2.75−$3.73−$6.75$1.13$0.14−$1.22
Surprise−3,511.1%+1,082.4%−127.3%−80.7%−70.4%+59.3%+622.2%

RevenueReportedEstimate

Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$1.52B$1.53B$1.39B$1.44B$1.57B$1.42B$1.49BPending
Estimate$1.52B$1.50B$1.47B$1.42B$1.47B$1.38B$1.45B$1.46B
Surprise+0.3%+1.9%−5.2%+1.0%+6.8%+2.9%+3.0%
Estimate−$1.22
ReportedDue Nov 3, 2026
Estimate$1.46B
ReportedDue Nov 3, 2026
View details

Debt to equity14.70%
Current ratio108.10%

ProfitabilityRevenueNet incomeNet margin

Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
Revenue$1.45B$1.52B$1.53B$1.39B$1.44B$1.57B$1.42B$1.49B
Net income−$117.6M−$105.8M$12.1M−$104.4M−$110.2M−$188.9M$30.0M$18.0M
Net margin0.0%0.0%0.8%0.0%0.0%0.0%2.1%1.2%

GrowthOperating income

Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
Operating income−$133.5M−$108.1M−$22.1M−$116.0M−$131.3M−$155.8M$10.1M$11.8M
YoY growthLoss widenedLoss narrowedLoss widenedLoss widenedLoss narrowedLoss widenedTurned profitTurned profit

Balance sheet, Jun 30, 2026Cash & short-term investments $185.6M · Total debt $33.4M · Total assets $1.59B · Shareholders' equity $227.5M

Revenue
$1.49B
Operating income
$11.8M
Net income
$18.0M
View details

No dividends on record.

Institutions≈ 97.20%16.32M shares
193 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail
Insiders5.84%980.6K shares
13 holders · as of Aug 18, 2026
Adds to103.04%

16.79M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing

This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.

A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.

These groups come from separate filings that can overlap, so they add to 103.04%; nothing is left for Other.

Top shareholders13F · 13D/G · Form 4

HolderStakeSharesDate
Clayton, Dubilier & Rice, LLCInstitution
23.82%4.00Mas of Jun 30, 2026
Morgan StanleyInstitution
11.98%2.01Mas of Jun 30, 2026
North Peak Capital Management, LLCInstitution
8.84%1.49Mas of Jun 30, 2026
BlackRock, Inc.Institution
6.83%1.15Mas of Jun 30, 2026
AQR Capital Management LLCInstitution
4.12%692,541as of Jun 30, 2026

Insider tradesForm 4

DateInsiderRoleSharesAvg price
Mar 2, 2026Benjamin Shakerofficer: Chief Markets Officer+500,000$0.6021
Nov 12, 2025John William Wulfdirector+81,000$0.6289
View details

  • UnitedHealth Group

    Scale alternative in MA, Optum value-based care, and provider enablement

  • CVS Health

    Aetna and Oak Street combine MA coverage with senior primary care

  • Humana

    Medicare Advantage and CenterWell senior primary care alternative

  • Astrana Health

    Risk-bearing physician platform across Medicare and multi-payer care

  • Privia Health

    Physician enablement and ACO platform for value-based contracts

  • Alignment Healthcare

    Medicare Advantage plan operator with tech-enabled senior care

  • P3 Health Partners

    Physician-led MA risk platform serving capitated members

  • Evolent

    Specialty-care value platform and former primary-care ACO owner

Compare

CompanyPriceChange
Agilon Health$83.44−3.92%$1.45B0.2+7.2%
UnitedHealth Group$368.47−1.20%$338.69B24.017.30.8+0.4%
CVS Health$85.99−1.27%$111.13B23.010.60.3+7.3%
Humana$371.06−0.23%$44.66B35.230.10.3+26.2%
Astrana Health$33.12−5.67%$1.74B42.920.00.5+48.5%
Privia Health$19.12−1.75%$2.45B89.749.71.0+21.4%
Alignment Healthcare$7.72−3.44%$1.66B42.827.90.4+31.6%
P3 Health Partners$7.42−1.33%$24.6M0.0+8.6%
Evolent$3.67−3.55%$427.4M10.90.2+46.9%
Median39.020.00.3+23.8%